Scinai Immunotherapeutics Reports Q2 2024 Results
Ticker: SCNI · Form: 6-K · Filed: Aug 15, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, business-update, foreign-private-issuer
TL;DR
Scinai Immunotherapeutics dropped its Q2 2024 earnings report and business update on Aug 15.
AI Summary
On August 15, 2024, Scinai Immunotherapeutics Ltd. (formerly BiondVax Pharmaceuticals Ltd.) filed a Form 6-K to report its Q2 2024 financial results and provide a business update. The company, incorporated in Israel, is involved in biological products and is headquartered at Jerusalem BioPark.
Why It Matters
This filing provides investors with an update on Scinai Immunotherapeutics' financial performance and business progress for the second quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain significant new risk factors.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Filer of the report
- BiondVax Pharmaceuticals Ltd. (company) — Former name of the registrant
- August 15, 2024 (date) — Date of the press release and filing
- Q2 2024 (period) — Financial reporting period
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report the registrant's Q2 2024 financial results and provide a business update, as announced in a press release dated August 15, 2024.
What was Scinai Immunotherapeutics Ltd. formerly known as?
Scinai Immunotherapeutics Ltd. was formerly known as BiondVax Pharmaceuticals Ltd.
When did the company change its name?
The company's name change from BiondVax Pharmaceuticals Ltd. to Scinai Immunotherapeutics Ltd. occurred on June 24, 2014.
Where is Scinai Immunotherapeutics Ltd. located?
The company's principal executive office is located at Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus, Jerusalem, Israel.
Does Scinai Immunotherapeutics file annual reports under Form 20-F or 40-F?
Scinai Immunotherapeutics indicates that it files annual reports under Form 20-F.
Filing Stats: 253 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-08-15 07:36:17
Filing Documents
- ea0211529-6k_scinai.htm (6-K) — 11KB
- ea021152901ex99-1_scinai.htm (EX-99.1) — 123KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- ex99-1_002.jpg (GRAPHIC) — 29KB
- 0001213900-24-069347.txt ( ) — 196KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 15, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2